Here's a problem: obesity affects over 100 million American adults and costs the U.S. economy more than $1.7 trillion every year. That's $480 billion in direct medical bills and a staggering $1.24 trillion in lost productivity, according to data from the Milken Institute.

And here's another problem: for about half of all commercially insured American workers, their employer-sponsored health plan doesn't cover the newer, highly effective medications designed to treat it.

On Wednesday, Eli Lilly and Company (LLY) rolled out a new strategy to tackle both issues at once. It's called Employer Connect, a platform designed specifically to help employers bridge that coverage gap for obesity medicines.

"For far too many people living with obesity, starting or staying on treatment isn't just a medical decision, it's an access decision driven by coverage and cost," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities.

Think of it as a one-stop shop for employers who want to add this benefit but might find the logistics daunting. The platform launches with more than 15 independent program administrators already on board, including names like 9amHealth, Calibrate Health, GoodRx, Mark Cuban's Cost Plus Drug Company, Teladoc Health, Transcarent, and Waltz Health. For the pharmacy side, HealthDyne and CenterWell are providing nationwide dispensing support.

The centerpiece of the offering is Lilly's own blockbuster weight-loss drug, Zepbound (tirzepatide). Through the platform, the Zepbound KwikPen—which was recently approved by the FDA for single-patient use and delivers four weekly injections—is available to network pharmacies at a flat price of $449. That price is the same across all doses.

Now, a quick but important note: that $449 is the price to the pharmacy. The final cost to an employer, and the out-of-pocket cost for an employee, will still depend on which program administrator they go through, any dispensing fees, and the specific cost-sharing model the employer sets up. But the idea is to create a more predictable and potentially more affordable pathway.

"This innovation can help employees access authentic obesity management medicines with more affordable out-of-pocket costs," said Kevin Hern, senior vice president of Lilly Employer.

Lilly isn't just selling convenience; it's selling results. The drug's efficacy is backed by clinical data. In the SURMOUNT-1 trial, adults taking the 15 mg dose of Zepbound lost an average of 20.9% of their body weight over 72 weeks, compared to just 3.1% for those on a placebo.

In the open-label SURMOUNT-5 study, which compared it directly to Novo Nordisk's injectable Wegovy (semaglutide), Zepbound users lost an average of 50 pounds (20.2% of body weight), while Wegovy users lost an average of 33 pounds (13.7%).

Of course, no medication is without its considerations. Zepbound carries a boxed warning—the FDA's strongest—for possible thyroid tumors, including thyroid cancer. It is also not approved for cosmetic weight loss, and individual results will vary.

For Lilly, this is a strategic move to expand the market for Zepbound by going directly to the source of a lot of health insurance in America: employers. If it works, it could unlock access for millions of people while addressing a trillion-dollar drag on the economy. It's a business solution to a public health and financial problem.

In early trading Thursday, Eli Lilly shares were down a negligible 0.06% at $1002.97, according to market data.